Breast Cancer

Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S.

An interim analysis of the PALLAS study showed that adding Ibrance to endocrine therapy, compared to endocrine therapy alone, after initial treatment ended for patients with HR-positive, HER2-negative, early-stage breast cancer did not extend the length of time before a patient’s disease recurred.

Runners will lace up “Everywhere, Together” to Finish Breast Cancer

In this episode of the “CURE Talks Cancer” podcast, we spoke with a patient who is receiving treatment for grade 3 triple-negative breast cancer. We talk about how a nurse’s question during a routine physical “saved her life”, and a kindness challenge she started to help lift her up during the dark days of treatment.

Regular aspirin use may increase survival in patients with bladder and breast cancer.

As a cancer survivor, I’ve found many reasons to celebrate. Here’s one more.

Janice and Rex Cowden sat down for an interview to discuss how to navigate a cancer diagnosis as a couple, and that communication is not only the key to a better cancer journey but a better marriage.

A cancer survivor discusses how she decides to discuss her mastectomy and the acceptance of her body after treatment for cancer.

It's easy to get lost in the statistics of survivorship, but it's important for newly diagnosed patients with cancer to remember that they are not a statistic.

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

The FDA’s fast track designation for ARX788 to treat patients with advanced or metastatic HER2-positive breast cancer who have received at least one previous anti-HER2-based treatment in the metastatic setting, may open the doors to an accelerated approval.

After being diagnosed with the BARD1 gene and undergoing a preventative double mastectomy, Nina Garcia shares her story to raise awareness and offer hope for other women.

In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.

Choosing to forego breast reconstruction after breast cancer surgery can cause one to feel like the lone ranger, but that feeling doesn’t last long, especially upon the discovery of an entire flattie tribe.

Here's how 3 clinical trials have shaped the overall landscape for patients with HER2 positive breast cancer.

A roundup of some of the most read news and updates in breast cancer in 2020 from CURE®.

Both younger and older women being treated for early breast cancer with chemotherapy are experiencing the same levels of symptom severity and find it a great concern as it interferes with their daily activities.

Highlighting a positive prognosis and improving education in treatment risk could result in lowering the overtreatment of older women who develop early-stage, hormone receptor-positive breast cancer.

How an app supported by Alexa has helped me answer cancer questions.

Catherine Stier, a breast cancer survivor, discusses her new book "When A Kid Like Me Has Cancer" a story of how to talk about cancer with children.

More than half of the patients with breast cancer who took part in an education-only or exercise-based intervention program remained lymphedema free 18 months following surgery to remove one or more of their lymph nodes.

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

While breast cancer survivors had a 45% higher risk of going into preterm labor, there were no significant increased risks of congenital defects or other pregnancy or delivery complications.

Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.

Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.

Recently presented data demonstrated that a combination of oral paclitaxel and Encequidar elicited promising results in patients with radiation-associated breast angiosarcoma.

Younger age, breast cancer diagnosis, Medicaid insurance and treatment type were associated with an increased risk for women becoming new chronic users of opioids or sedatives/hypnotics following mastectomy with reconstructive surgery.

This week on the “CURE Talks Cancer” podcast, we discuss the power of community with The Breasties co-founders Brianna Majsiak and Allie Brudner Brumel and how their own experiences with breast cancer brought them together.

Several factors may lead to prolonged treatment duration for breast cancer including socioeconomic status, race, and barriers to care.